SHIGA UNIVERSITY

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Private

Established: 1949-01-01

Employees: -

Market Cap: -

Website: http://www.shiga-u.ac.jp

Clinical Trials

Night in Japan Home Sleep Monitoring Study

Conditions: Depression
Sleep Initiation and Maintenance Disorders

First Posted Date: 2017-09-08

Last Posted Date: 2018-04-20

Lead Sponsor: Shiga University

Target Recruit Count: 2000

Registration Number: NCT03276585

Locations: 🇯🇵
Shiga University of Medical Science, Otsu, Shiga, Japan

A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer

Completed

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2015-02-18

Last Posted Date: 2020-09-01

Lead Sponsor: Shiga University

Target Recruit Count: 10

Registration Number: NCT02364804

Locations: 🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant

First Posted Date: 2013-09-25

Last Posted Date: 2019-03-19

Lead Sponsor: Shiga University

Target Recruit Count: 6

Registration Number: NCT01950156

Locations: 🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A24 or A02-positive Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Biological: HLA-A*2402 or A*0201 restricted peptides

First Posted Date: 2013-09-24

Last Posted Date: 2019-03-19

Lead Sponsor: Shiga University

Target Recruit Count: 26

Registration Number: NCT01949688

Locations: 🇯🇵
Shiga University of Medical Science Hospital, Ohtsu, Shiga, Japan

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: HLA-A*0201restricted URLC10 peptides with adjuvant

First Posted Date: 2013-09-24

Last Posted Date: 2019-03-19

Lead Sponsor: Shiga University

Target Recruit Count: 6

Registration Number: NCT01949701

Locations: 🇯🇵
Shiga University of Medical Science Hospital, Ohtsu, Shiga, Japan

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: S-488410

First Posted Date: 2012-05-07

Last Posted Date: 2015-08-13

Lead Sponsor: Shiga University

Target Recruit Count: 45

Registration Number: NCT01592617

Locations: 🇯🇵
Department of Medical Oncology, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan

Shiga Microalbuminuria Reduction Trial-2

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Hypertension

Interventions: Drug: any angiotensin receptor blockers
Drug: Aliskiren

First Posted Date: 2011-10-28

Last Posted Date: 2018-02-19

Lead Sponsor: Shiga University

Target Recruit Count: 237

Registration Number: NCT01461499

Locations: 🇯🇵
Shiga University of Medical Science, Otsu, Shiga, Japan

The Effect of Sacral Surface Electrical Stimulation for Assisted Reproductive Technology

Phase 1

Conditions: Infertility

Interventions: Device: SSE

First Posted Date: 2010-03-09

Last Posted Date: 2010-03-09

Lead Sponsor: Shiga University

Target Recruit Count: 100

Registration Number: NCT01082913

Locations: 🇯🇵
Shiga University of Medical Science, Ohtsu, Shiga, Japan

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides

First Posted Date: 2010-02-17

Last Posted Date: 2019-03-19

Lead Sponsor: Shiga University

Target Recruit Count: 9

Registration Number: NCT01069640

Locations: 🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides

First Posted Date: 2010-02-17

Last Posted Date: 2019-03-19

Lead Sponsor: Shiga University

Target Recruit Count: 18

Registration Number: NCT01069575

Locations: 🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy